Article in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Mary W BrodenDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0001-6492-1253
Jutamas ShaughnessyDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Frida MohlinDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Amaris J CardenasDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Anna M BlomDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Sanjay RamDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.ORCID 0000-0003-0058-9532
Alison K CrissDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0001-7738-3757
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR37AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI Alison K Criss · 2025 to 2026
$1.1M
Bispecific antibody for topical administration to prevent gonorrheaR43AI186979 · NIAID · PLANET BIOTECHNOLOGY, INC. · PI RAM, SANJAY, WYCOFF, KEITH · 2024 to 2025
$600k
A broad spectrum anti-gonorrhea immunotherapeuticR41AI179576 · NIAID · PLANET BIOTECHNOLOGY, INC. · PI SHAUGHNESSY, JUTAMAS, WYCOFF, KEITH · 2024 to 2025
$597k
Cytek Aurora CSS10OD034355 · OD · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2023 to 2023
$595k
Sony MA900 Cell SorterS10OD028518 · OD · UNIVERSITY OF VIRGINIA · PI BENDER, TIMOTHY P. · 2020 to 2020
$359k
Contribution of C4b-binding protein to interactions of Neisseria gonorrhoeae with human neutrophilsF31AI188753 · NIAID · UNIVERSITY OF VIRGINIA · PI Mary Wakim Broden · 2025 to 2026
$79k
Investigating the role of lipooligosaccharide sialylation in Neisseria gonorrhoeae-neutrophil interactionsF31AI157528 · NIAID · UNIVERSITY OF VIRGINIA · PI CARDENAS, AMARIS J. · 2021 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
C4BP occludes the non-opsonic interaction of · full record | OpenQuestion